InteRNA Technologies secures 18.5m in Series B financing
MicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling 18.5m led by AurorA Science, an Italian biotech investment company.
German Health Ministry to invest 6.2bn in vaccines
The German Health Ministry has requested 6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.
V-Bio Ventures launches second fund at 78m
V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at 78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the EU.
·
Abingworth raises US-$465m for new life sciences fund
The transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.
Two companies aim for 2nd-gen COVID vaccines
As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.
Rentschler Biopharma to produce 100m doses of CureVac vaccine
German CDMO Rentschler Biopharma is expanding cCMP production of CureVac NVs RNA-based COVID-19 vaccine candidate CVnCoV.
Italian Enthera Pharma raise 35m in Series A extension
Enthera Pharmaceuticals extends its 28m Series A financing from last July to a total of 35m as Roche Venture Fund joins the companys investor syndicate.
German antibodies in demand in USA
A US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2.
Omnix Medical bags 10.8m from EIC Accerator Fund
Israels Omnix Medical has been granted 10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs.
Germany orders antibody therapies from USA
Germany has become the first country in Europe to buy the US emergency-approved COVID-19 antibody therapies from Regeneron and Eli Lilly.